Structure of β-antithrombin and the effect of glycosylation on antithrombin's heparin affinity and activity

Journal of Molecular Biology

Volumn 326, Issue 3, 2003, Pages 823-833

  McCoy, Airlie J ^a   Pei, Xue Yuan ^b   Skinner, Richard ^c   Abrahams, Jan Pieter ^d   Carrell, Robin W ^a  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^c UNILEVER RESEARCH   (United Kingdom)

^d LEIDEN UNIVERSITY   (Netherlands)

Author keywords

Carbohydrate; Crystal structure; Glycosylation; Heparin; Serpin

Indexed keywords

ALPHA ANTITHROMBIN; ANTITHROMBIN; ASPARAGINE; BETA ANTITHROMBIN; CARBOHYDRATE; HEPARIN DERIVATIVE; HEPARIN PENTASACCHARIDE; PENTASACCHARIDE; UNCLASSIFIED DRUG;

ARTICLE; BINDING AFFINITY; CONFORMATIONAL TRANSITION; CRYSTAL STRUCTURE; DRUG ACTIVITY; DRUG PROTEIN BINDING; MODEL; PRIORITY JOURNAL; PROTEIN CONFORMATION; PROTEIN GLYCOSYLATION; PROTEIN STRUCTURE; STEREOSPECIFICITY;

EID: 0037459052     PISSN: 00222836     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-2836(02)01382-7     Document Type: Article

References (40)

1. Olson S.T., Bjork I. Regulation of thrombin activity by antithrombin and heparin. Semin. Thromb. Haemost. 20:1994;373-409.
2. Marcum J.A., Rosenberg R.D. Anticoagulant active heparin-like molecules from vascular tissue. Biochemistry. 23:1984;1730-1737.
3. Craig P.A., Olson S.T., Shore J.D. Transient kinetics of heparin-catalyzed protease inactivation by antithrombin III. Characterization of assembly, product formation, and heparin dissociation steps in the factor Xa reaction. J. Biol. Chem. 264:1989;5452-5461.
4. Petitou M., HÈrault J.-P., Bernat A., Driguez P.-A., Duchaussoy P., Lormeau J.-C., Herbert J.-M. Synthesis of thrombin-inhibiting heparin mimetics without side effects. Nature. 398:1999;417-422.
5. Turk B., Brieditis I., Bock S.C., Olson S.T., Bjork I. The oligosaccharide side chain on Asn-135 of alpha-antithrombin, absent in beta-antithrombin, decreases the heparin affinity of the inhibitor by affecting the heparin-induced conformational change. Biochemistry. 36:1997;6682-6691.
6. Turko I.V., Fan B.Q., Gettins P.G.W. Carbohydrate isoforms of antithrombin variant N135Q with difference heparin affinities. FEBS Letters. 335:1993;9-12.
7. Peterson C.B., Blackburn M.N. Isolation and characterization of an antithrombin-II variant with reduced carbohydrate content and enhanced heparin binding. J. Biol. Chem. 260:1985;610-615.
8. Witmer M.R., Hatton M.W. Antithrombin-III-beta associates more readily thatn antithrombin-III-alpha with uninjured and deendothelialized aortin-wall in vitro and in vivo. Arterioscler. Thromb. 11:1991;530-539.
9. Frebelius S., Isaksson S., Swedenborg J. Thrombin inhibition by antithrombin III on the subendothelium is explained by the isoform antithrombin beta. Arterioscler. Thromb. Vasc. Biol. 16:1996;1292-1297.
10. Swedenborg J. The mechanisms of action of alpha- and beta-isoforms of antithrombin. Blood Coagul. Fibrinolysis. 9:1998;S7-S10.
11. Zettlmeissl G., Conradt H.S., Nimtz M., Karges H.E. Characterization of recominant human antithrombin-III synthesised in chinese-hamster ovary cells. J. Biol. Chem. 264:1989;21153-21159.
12. Fitches A.C., Appleby R., Lane D.A., DeStefano V., Leone G., Olds R.J. Impaired cotranslational processing as a mechanism for type I antithrombin deficiency. Blood. 92:1998;4671-4676.
13. Kasturi L., Eshleman J.R., Wunner W.H., Shakin-Eshleman S.H. The hydroxy amino acid in an Asn-X-Ser/Thr sequon can influence N-linked core glycosylation efficiency and the level of expression of a cell surface glycoprotein. J. Biol. Chem. 270:1995;14756-14761.
14. Brennan S.O., Borg J.Y., George P.M., Soria C., Soria J., Caen J., Carrell R.W. New carbohydrate site in mutant antithrombin (7-ILE-ASN) with decreased heparin affinity. FEBS Letters. 237:1988;118-122.
15. Carlson T.H., Atencio A.C., Simon T.L. Comparison of the behaviour in vivo of 2 molecular forms of anthithrombin-III. Biochem. J. 225:1985;557-564.
16. Carrell R.W., Stein P.E., Wardell M.R., Fermi G. Biological implications of a 3 angstrom structure of dimeric antithrombin. Structure. 2:1994;257-270.
17. Schreuder H.A., de Boer B., Dijkema R., Mulders J., Theunissen H.J.M., Grootenhuis P.D.J., Hol W.G.J. The intact and cleaved human antithrombin-II complex as a model for serpin-protease interactions. Nature Struct. Biol. 1:1994;48-54.
18. Jin L., Abrahams J.P., Skinner R., Petitou M., Pike R.N., Carrell R.W. The anticoagulant activation of antithrombin by heparin. Proc. Natl Acad. Sci. USA. 94:1997;14683-14688.
19. Schechter L., Berger A. On the size of the active site in proteases. I. Papain. Biochem. Bioophys. Res. Commun. 27:1967;157-162.
20. Huntington J.A., Read R.J., Carrell R.W. Structure of a serpin-protease complex shows inhibition through deformation. Nature. 407:2000;923-926.
21. Zhou A.W., Huntington J.A., Carrell R.W. Formation of the antithrombin heterodimer in vivo and the onset of thrombosis. Blood. 94:1999;3388-3396.
22. Skinner R., Abrahams J.P., Whisstock J.C., Lesk A.M., Carrell R.W., Wardell M.R. The 2.6 angstrom structure of antithrombin indicates a conformational change at the heparin binding site. J. Mol. Biol. 266:1997;601-609.
23. Murshudov G.N., Vagin A.A., Dodson E.J. Refinement of macromolecular structures by the maximum-likelihood method. Acta Crystallog. sect. D. 53:1997;240-255.
24. The CCP4 suite: programs for protein crystallography. Acta Crystallog. sect. D. 50:1994;760-763.
25. Brunger A.T. XPLOR: Version 3.1. A System for Protein Crystallography and NMR. 1993;Yale University Press, New Haven, CT, USA.
26. Jones T.A., Zou J.Y., Cowan S.W., Kjeldgaard M. Improved methods for building protein models in electron density maps and the location of errors in these models. Acta Crystallog. sect. A. 47:1991;110-119.
27. Picard V., Ersdal-Badju E., Bock S.C. Partial glycosylation of antithrombin-III asparagine-135 is caused by the serine in the 3rd position of its N-glycosylation consensus sequence and is reponsible for production of the beta-antithromibin-III isoform with enhanced heparin affinity. Biochemistry. 34:1995;8433-8440.
28. Lane D.A., Bayston T., Olds R.J., Fitches A.C., Cooper D.N., Millar D.S., et al. Antithrombin mutation database: 2nd (1997) update - for the plasma coagulation inhibitors subcommittee of the scientific and standardization committee of the international society on thrombosis and haemostasis. Thromb. Haemost. 77:1997;197-211.
29. Bayston T.A., Tripodi A., Mannucci P.M., Thompson E., Ireland H., Fitches A.C., et al. Familial overexpression of beta antithrombin caused by an Asn135Thr substitution. Blood. 93:1999;4242-4247.
30. Olson S.T., Frances-Chmura A.M., Swanson R., Bjork I., Zettlmeissl G. Effect of individual carbohydrate chains of recombinant antithrombin on heparin affinity and on the generation of glycoforms differing in heparin affinity. Arch. Biochem. Biophys. 341:1997;212-221.
31. Carchon H., Van Schaftingen E., Matthijs G., Jaeken J. Carbohydrate-deficient glycoprotein syndrome type IA (phosphomannomutase-deficiency). Biochim, Biophys. Acta. 1455:1999;155-165.
32. Young G., Driscoll M.C. Coagulation abnormalities in the carbohydrate-deficient glycoprotein syndrome: case report and review of the literature. Am. J. Hematol. 60:1999;66-69.
33. Stibler H., Holzbach U., Kristiansson B. Isoforms and levels of transferrin, antithrombin, alpha(1)- antitrypsin and thyroxine-binding globulin in 48 patients with carbohydrate-deficient glycoprotein syndrome type I. Scand. J. Clin. Lab. Invest. 58:1998;55-61.
34. Bjork I., Ylinenjarvi K., Olson S.T., Hermentin P., Conradt H.S., Zettlemeissl G. Decreased affinity of recombinant antithrombin for heparin due to increased glycosylation. Biochem. J. 286:1992;793-800.
35. McKay E.J. A simple two-step procedure for the isolation of antithrombin III from biological fluids. Thromb. Res. 21:1981;375-382.
36. Navaza J. AMoRe: an automated package for molecular replacement. Acta Crystallog. sect. A. 50:1994;157-163.
37. Mizuochi T., Fujii J., Kurachi K., Kobata A. Structural studies of the carbohydrate moiety of human antithrombin III. Arch. Biochem. Biophys. 203:1980;458-465.
38. Franzén L.-E., Svensson S., Larm O. Structural studies on the carbohydrate portion of human antithrombin III. J. Biol. Chem. 255:1980;5090-5093.
39. Esnouf R.M. An extensively modified version of MolScript that includes greatly enhanced coloring capabilities. J. Mol. Graph. 15:1997;133-138.
40. Kraulis P. MOLSCRIPT: a program to produce both detailed and schematic structures. J. Appl. Crystallog. 24:1991;946-950.